Mga Batayang Estadistika
| CIK | 1071272 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Parallel Industries Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| December 30, 2021 |
TABLE OF CONTENTS PART I – FINANCIAL INFORMATION Item 1. Unaudited Interim Consolidated Financial Statements Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Item 3. Quantitative and Qualitative Disclosures About Market Risk Item 4. Controls and Procedures PART II – OTHER INFORMATION Item 1. Legal Proceedings Item 1A. Risk Factors Item 2. Unregistered S |
|
| December 30, 2021 |
TABLE OF CONTENTS PART I – FINANCIAL INFORMATION Item 1. Unaudited Interim Consolidated Financial Statements Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Item 3. Quantitative and Qualitative Disclosures About Market Risk Item 4. Controls and Procedures PART II – OTHER INFORMATION Item 1. Legal Proceedings Item 1A. Risk Factors Item 2. Unregistered S |
|
| December 30, 2021 |
TABLE OF CONTENTS PART I – FINANCIAL INFORMATION Item 1. Unaudited Interim Consolidated Financial Statements Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Item 3. Quantitative and Qualitative Disclosures About Market Risk Item 4. Controls and Procedures PART II – OTHER INFORMATION Item 1. Legal Proceedings Item 1A. Risk Factors Item 2. Unregistered S |
|
| December 29, 2021 |
TABLE OF CONTENTS PART I – FINANCIAL INFORMATION Item 1. Unaudited Interim Consolidated Financial Statements Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Item 3. Quantitative and Qualitative Disclosures About Market Risk Item 4. Controls and Procedures PART II – OTHER INFORMATION Item 1. Legal Proceedings Item 1A. Risk Factors Item 2. Unregistered S |
|
| December 29, 2021 |
10-K/A 1 EAPHEDGARfilingDec3120.htm TABLE OF CONTENTS PART I Item 1. Business Item 1A. Risk Factors Item 1B. Unresolved Staff Comments Item 2. Properties Item 3. Legal Proceedings Item 4. Mine Safety Disclosures PART II Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities Item 6. Selected Financial Data Item 7. Management’s Discussion |
|
| December 29, 2021 |
10-K/A 1 EAPHEDGARfilingDec3119.htm TABLE OF CONTENTS PART I Item 1. Business Item 1A. Risk Factors Item 1B. Unresolved Staff Comments Item 2. Properties Item 3. Legal Proceedings Item 4. Mine Safety Disclosures PART II Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities Item 6. Selected Financial Data Item 7. Management’s Discussion |
|
| December 22, 2021 |
TABLE OF CONTENTS PART I – FINANCIAL INFORMATION Item 1. Unaudited Interim Consolidated Financial Statements Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Item 3. Quantitative and Qualitative Disclosures About Market Risk Item 4. Controls and Procedures PART II – OTHER INFORMATION Item 1. Legal Proceedings Item 1A. Risk Factors Item 2. Unregist |
|
| December 22, 2021 |
TABLE OF CONTENTS PART I – FINANCIAL INFORMATION Item 1. Unaudited Interim Consolidated Financial Statements Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Item 3. Quantitative and Qualitative Disclosures About Market Risk Item 4. Controls and Procedures PART II – OTHER INFORMATION Item 1. Legal Proceedings Item 1A. Risk Factors Item 2. Unregistered S |
|
| December 22, 2021 |
TABLE OF CONTENTS PART I Item 1. Business Item 1A. Risk Factors Item 1B. Unresolved Staff Comments Item 2. Properties Item 3. Legal Proceedings Item 4. Mine Safety Disclosures PART II Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities Item 6. Selected Financial Data Item 7. Management’s Discussion and Analysis of Financial Condition |
|
| December 22, 2021 |
TABLE OF CONTENTS PART I – FINANCIAL INFORMATION Item 1. Unaudited Interim Consolidated Financial Statements Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Item 3. Quantitative and Qualitative Disclosures About Market Risk Item 4. Controls and Procedures PART II – OTHER INFORMATION Item 1. Legal Proceedings Item 1A. Risk Factors Item |
|
| December 22, 2021 |
10-K 1 EAPHEDGARfilingDec3120.htm TABLE OF CONTENTS PART I Item 1. Business Item 1A. Risk Factors Item 1B. Unresolved Staff Comments Item 2. Properties Item 3. Legal Proceedings Item 4. Mine Safety Disclosures PART II Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities Item 6. Selected Financial Data Item 7. Management’s Discussion a |
|
| September 29, 2016 |
Easton Pharmaceuticals PART II AND III PART II AND III OFFERING CIRCULAR Easton Pharmaceuticals Inc. 1,666,666,666 SHARES OF COMMON STOCK MAXIMUM OFFERING: $5,000,000 Purchase Price: $0.003 per share Easton Pharmaceuticals Inc., a Wyoming corporation (?Easton Pharmaceuticals? the ?Company,? or ?we?) hereby offers (the ?Offering?) 1,666,666,666 shares (the ?Shares?) of its common stock, par value $0.0001 per share (the ?Common Stock?) a |
|
| September 29, 2016 |
Easton Pharmaceuticals OPINION RE/ LEGALITY Opinion re/ legality PART III - EXHIBIT 4 OPINION RE: LEGALITY 1650 Market Street One Liberty Place, Suite 1800 Philadelphia, PA 19103-7395 whiteandwilliams. |
|
| September 29, 2016 |
Easton Pharmaceuticals MATERIAL CONTRACTS - EMPLOYMENT AGREEMENTS Material contracts - Employment Agreements PART III ? EXHIBIT 3 MATERIAL CONTRACTS ? Employment Agreements of Carla Pepe, Dr. |
|
| September 29, 2016 |
Easton Pharmaceuticals SUBSCRIPTION AGREEMENT Subscription agreement PART III - EXHIBIT 2 SUBSCRIPTION AGREEMENT SUBSCRIPTION AGREEMENT Print Name of Subscriber: Amount Invested $ Number of Shares: Easton Pharmaceuticals Inc. |
|
| September 29, 2016 |
Easton Pharmaceuticals CERTIFICATE OF INCORPORATION AND BY-LAWS EX1A-2B BYLAWS 3 d451422dex1a2bbylaws.htm CERTIFICATE OF INCORPORATION AND BY-LAWS PART III – EXHIBIT 1 CERTIFICATE OF INCORPORATION AND BY-LAWS By-Laws of L.A.M Pharmaceuticals (A Wyoming Corporation) ARTICLE I OFFICES Section 1.01 Offices. The Corporation shall have its registered office in the State of Wyoming, and may have such other offices and places of business within or without the State o |
|
| August 22, 2016 |
Easton Pharmaceuticals PART II AND III PART II AND III OFFERING CIRCULAR Easton Pharmaceuticals Inc. 1,666,666,666 SHARES OF COMMON STOCK MAXIMUM OFFERING: $5,000,000 Purchase Price: $0.003 per share Easton Pharmaceuticals Inc., a Wyoming corporation (?Easton Pharmaceuticals? the ?Company,? or ?we?) hereby offers (the ?Offering?) 1,666,666,666 shares (the ?Shares?) of its common stock, par value $0.0001 per share (the ?Common Stock?) a |
|
| August 22, 2016 |
Easton Pharmaceuticals OPINION RE/ LEGALITY Opinion re/ legality PART III - EXHIBIT 4 OPINION RE: LEGALITY 1650 Market Street One Liberty Place, Suite 1800 Philadelphia, PA 19103-7395 whiteandwilliams. |
|
| August 22, 2016 |
Easton Pharmaceuticals OPINION RE/ LEGALITY Opinion re/ legality PART III - EXHIBIT 4 OPINION RE: LEGALITY 1650 Market Street One Liberty Place, Suite 1800 Philadelphia, PA 19103-7395 whiteandwilliams. |
|
| August 22, 2016 |
Easton Pharmaceuticals SUBSCRIPTION AGREEMENT Subscription agreement PART III - EXHIBIT 2 SUBSCRIPTION AGREEMENT SUBSCRIPTION AGREEMENT Print Name of Subscriber: Amount Invested $ Number of Shares: Easton Pharmaceuticals Inc. |
|
| August 22, 2016 |
Easton Pharmaceuticals MATERIAL CONTRACTS - EMPLOYMENT AGREEMENTS Material contracts - Employment Agreements PART III ? EXHIBIT 3 MATERIAL CONTRACTS ? Employment Agreements of Carla Pepe, Dr. |
|
| August 22, 2016 |
Easton Pharmaceuticals SUBSCRIPTION AGREEMENT Subscription agreement PART III - EXHIBIT 2 SUBSCRIPTION AGREEMENT SUBSCRIPTION AGREEMENT Print Name of Subscriber: Amount Invested $ Number of Shares: Easton Pharmaceuticals Inc. |
|
| August 22, 2016 |
Easton Pharmaceuticals CERTIFICATE OF INCORPORATION AND BY-LAWS Certificate of Incorporation and by-laws PART III ? EXHIBIT 1 CERTIFICATE OF INCORPORATION AND BY-LAWS Wyoming State Capitol Building, Room 110 200 West 24th Street Cheyenne, WY 82002-0020 Ph. |
|
| August 22, 2016 |
Easton Pharmaceuticals PART II AND III PART II AND III OFFERING CIRCULAR Easton Pharmaceuticals Inc. 1,666,666,666 SHARES OF COMMON STOCK MAXIMUM OFFERING: $5,000,000 Purchase Price: $0.003 per share Easton Pharmaceuticals Inc., a Wyoming corporation (?Easton Pharmaceuticals? the ?Company,? or ?we?) hereby offers (the ?Offering?) 1,666,666,666 shares (the ?Shares?) of its common stock, par value $0.0001 per share (the ?Common Stock?) a |
|
| August 22, 2016 |
Easton Pharmaceuticals CERTIFICATE OF INCORPORATION AND BY-LAWS Certificate of Incorporation and by-laws PART III ? EXHIBIT 1 CERTIFICATE OF INCORPORATION AND BY-LAWS Wyoming State Capitol Building, Room 110 200 West 24th Street Cheyenne, WY 82002-0020 Ph. |
|
| May 17, 2016 |
Easton Pharmaceuticals EX1A-2B BYLAWS EX1A-2B BYLAWS PART III ? EXHIBIT 1 CERTIFICATE OF INCORPORATION AND BY-LAWS Wyoming State Capitol Building, Room 110 200 West 24th Street Cheyenne, WY 82002-0020 Ph. |
|
| May 17, 2016 |
Easton Pharmaceuticals PART II AND III PART II AND III Table of Contents OFFERING CIRCULAR Easton Pharmaceuticals Inc. 1,666,666,666 SHARES OF COMMON STOCK MAXIMUM OFFERING: $5,000,000 Purchase Price: $0.003 per share Easton Pharmaceuticals Inc., a Wyoming corporation (?Easton Pharmaceuticals? the ?Company,? or ?we?) hereby offers (the ?Offering?) 1,666,666,666 shares (the ?Shares?) of its common stock, par value $0.0001 per share (the |
|
| May 17, 2016 |
Easton Pharmaceuticals EX1A-6 MAT CTRCT EX1A-6 MAT CTRCT PART III ? EXHIBIT 3 MATERIAL CONTRACTS ? Employment Agreements of [***] EMPLOYMENT AGREEMENT This Management and Employment Agreement, effective November 01, 2013, is entered into, by and between Easton Pharmaceuticals Inc. |
|
| May 17, 2016 |
Easton Pharmaceuticals EX1A-12 OPN CNSL EX1A-12 OPN CNSL PART III - EXHIBIT 4 OPINION RE: LEGALITY 1650 Market Street One Liberty Place, Suite 1800 Philadelphia, PA 19103-7395 whiteandwilliams. |
|
| May 17, 2016 |
Easton Pharmaceuticals EX1A-4 SUBS AGMT EX1A-4 SUBS AGMT PART III - EXHIBIT 2 SUBSCRIPTION AGREEMENT SUBSCRIPTION AGREEMENT Print Name of Subscriber: Amount Invested $ Number of Shares: Easton Pharmaceuticals Inc. |
|
| March 25, 2016 |
Easton Pharmaceuticals EX1A-4 SUBS AGMT EX1A-4 SUBS AGMT PART III - EXHIBIT 2 SUBSCRIPTION AGREEMENT SUBSCRIPTION AGREEMENT Print Name of Subscriber: Amount Invested $ Number of Shares: Easton Pharmaceuticals Inc. |
|
| March 25, 2016 |
Easton Pharmaceuticals PART II AND III PART II AND III Table of Contents OFFERING CIRCULAR Easton Pharmaceuticals Inc. 1,666,666,666 SHARES OF COMMON STOCK MAXIMUM OFFERING: $5,000,000 Purchase Price: $0.003 per share Easton Pharmaceuticals Inc., a Wyoming corporation (?Easton Pharmaceuticals? the ?Company,? or ?we?) hereby offers (the ?Offering?) 1,666,666,666 shares (the ?Shares?) of its common stock, par value $0.0001 per share (the |
|
| March 25, 2016 |
Easton Pharmaceuticals EX1A-2B BYLAWS EX1A-2B BYLAWS PART III ? EXHIBIT 1 CERTIFICATE OF INCORPORATION AND BY-LAWS Wyoming State Capitol Building, Room 110 200 West 24th Street Cheyenne, WY 82002-0020 Ph. |
|
| March 25, 2016 |
Easton Pharmaceuticals EX1A-6 MAT CTRCT EX1A-6 MAT CTRCT PART III ? EXHIBIT 3 MATERIAL CONTRACTS ? Employment Agreements of [***] EMPLOYMENT AGREEMENT This Management and Employment Agreement, effective November 01, 2013, is entered into, by and between Easton Pharmaceuticals Inc. |
|
| March 25, 2016 |
Easton Pharmaceuticals EX1A-12 OPN CNSL EX1A-12 OPN CNSL PART III - EXHIBIT 4 OPINION RE: LEGALITY 1650 Market Street One Liberty Place, Suite 1800 Philadelphia, PA 19103-7395 whiteandwilliams. |
|
| March 1, 2016 |
Easton Pharmaceuticals PART II AND III PART II AND III PART II ? INFORMATION REQUIRED IN OFFERING CIRCULAR (a) Financial statement requirements regardless of the applicable disclosure format are specified in Part F/S of this Form 1-A. |
|
| January 29, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 000-30641 L.A.M. PHARMACEUTICAL, CORP. (Exact name of registrant as specifi |
|
| November 21, 2005 |
Filed by Automated Filing Services Inc. (604) 609-0244 - L.A.M. Pharmaceutical, Corp. - Form 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB x Quarterly Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2005 or ¨ Transition Report under Section 13 or 15 (d) of the Securities Exchange Act of |
|
| November 14, 2005 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): SEC FILE NUMBER 000-30641 CUSIP NUMBER N/A ¨ Form 10-KSB ¨ Form 20-F ¨ Form 11-K x Form 10-QSB ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: September 30, 2005 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Tran |
|
| August 15, 2005 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB x Quarterly Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2005 or ¨ Transition Report under Section 13 or 15 (d) of the Securities Exchange Act of 1934 Commission file No. 000-30641 L.A.M. PHARMACEUTICAL, CORP. (Exact name of registrant as specified |
|
| July 19, 2005 |
Stock Bonus Plan (as amended on April 29, 2005). EX-4.1 2 exhibit4-4.htm STOCK BONUS PLAN (AS AMENDED ON APRIL 29, 2005). Exhibit 4.4 L.A.M. PHARMACEUTICAL, CORP. STOCK BONUS PLAN (As amended on April 29, 2005) l. Purpose. The purpose of this Stock Bonus Plan is to advance the interests of L.A.M. Pharmaceutical, Corp. (the “Company”) and its shareholders, by encouraging and enabling selected officers, directors, consultants and key employees upo |
|
| July 19, 2005 |
Filed by Automated Filing Services Inc. (604) 609-0244 - L.A.M. Pharmaceutical, Corp. - Form S-8 As filed with the Securities and Exchange Commission on July 19, 2005. Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 L.A.M. PHARMACEUTICAL, CORP. (Exact name of registrant as specified in its cha |
|
| July 7, 2005 |
L.A.M. PHARMACEUTICAL, CORP. Common Stock 22,037,182 Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333-125554 Prospectus L.A.M. PHARMACEUTICAL, CORP. Common Stock 22,037,182 Shares This prospectus covers the sale of a total of 22,037,182 shares of our common stock being offered by the selling stockholders. Of the shares covered by this prospectus, 16,162,676 shares have been issued and 5,874,506 shares are issuable upon exercise of warrants issu |
|
| June 27, 2005 |
EX-4.4 2 exhibit4-4.htm FORM OF SUBSCRIPTION AGREEMENT Exhibit 4.4 Form of Subscription Agreement to Purchase Common Stock and Warrants issued by the Registrant to the Selling Stockholders SUBSCRIPTION AGREEMENT 1. Subscription. I hereby agree to purchase the following securities offered by L.A.M. Pharmaceutical, Corp. (the "Company") in accordance with the terms of this Subscription Agreement. No |
|
| June 27, 2005 |
As filed with the Securities and Exchange Commission on June 27, 2005 Registration No. |
|
| June 6, 2005 |
EX-4.4 2 exhibit4-4.htm FORM OF SUBSCRIPTION AGREEMENT Exhibit 4.4 Form of Subscription Agreement to Purchase Common Stock and Warrants issued by the Registrant to the Selling Stockholders SUBSCRIPTION AGREEMENT 1. Subscription. I hereby agree to purchase the following securities offered by L.A.M. Pharmaceutical, Corp. (the "Company") in accordance with the terms of this Subscription Agreement. No |
|
| June 6, 2005 |
As filed with the Securities and Exchange Commission on June 6, 2005 Registration No. |
|
| May 16, 2005 |
Filed by Automated Filing Services Inc. (604) 609-0244 - L.A.M. Pharmaceutical Corp. - Form 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB x Quarterly Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2005 or ¨ Transition Report under Section 13 or 15 (d) of the Securities Exchange Act of 193 |
|
| March 31, 2005 |
Filed by Automated Filing Services Inc. (604) 609-0244 - L.A.M. Pharmaceutical, Corp. - Form 10-KSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2004 Commission File No. 000-30641 L.A.M. PHARMACEUTICAL, CORP. (Exact name of registrant as |
|
| January 18, 2005 |
Exhibit 10.1 Stock Bonus Plan (as amended on January 17, 2005). Exhibit 10.1 L.A.M. PHARMACEUTICAL, CORP. STOCK BONUS PLAN (As amended on January 17, 2005) l. Purpose. The purpose of this Stock Bonus Plan is to advance the interests of L.A.M. Pharmaceutical, Corp. (the ?Company?) and its shareholders, by encouraging and enabling selected officers, directors, consultants and key employees upon whose judgment, initiative and effort the Company is largely depende |
|
| January 18, 2005 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 17, 2005 L.A.M. PHARMACEUTICAL, CORP. (Exact name of registration as specified in its charter) Delaware 0-30641 52-2278236 (State or other jurisdiction (Commission File Number) |
|
| January 18, 2005 |
Filed by Automated Filing Services Inc. (604) 609-0244 - L.A.M. Pharmaceutical, Corp. - Form S-8 As filed with the Securities and Exchange Commission on January 18, 2005. Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 L.A.M. PHARMACEUTICAL, CORP. (Exact name of registrant as specified in its |
|
| January 11, 2005 |
Financial Statements and Exhibits, Other Events 8-K 1 htm2599.htm LIVE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 5, 2005 L.A.M. Pharmaceutical, Corp. (Exact name of registrant as specified in its charter) Delaware 000-30641 52-2278236 (State or other jurisdi |
|
| January 11, 2005 |
LAM Pharmaceutical to Acquire Pharmaceutical Company in China L.A.M. Pharmaceutical, Corp. PRESS RELEASE Exhibit 99.1 For immediate Release January 11, 2005 For more information contact: Stephanie Carrington (Investors/Media) 646-536-7017 The Ruth Group LAM Pharmaceutical to Acquire Pharmaceutical Company in China Lewiston, N.Y., January 11, 2005 ? LAM Pharmaceutical, Corp. (OTC BB: LAMP; Frankfurt: LAM; Berlin: LAM), a biomedical company focused on the deve |
|
| January 7, 2005 |
L.A.M. Pharmaceutical Inc. UNITED STATES SECURITITES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 4, 2005 L.A.M. PHARMACEUTICAL, CORP. (Exact name of registration as specified in its charter) Delaware 0-30641 52-2278236 (State or other jurisdicti |
|
| November 12, 2004 |
L.A.M. PHARMACEUTICALS FORM 10QSB Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB þ Quarterly Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2004 or o Transition Report under Section 13 or 15 (d) of the Securities Exchange Act of 1934 Commission file No. 000-30641 L.A.M. PHARMA |
|
| October 20, 2004 |
Exhibit 10.7 L.A.M. PHARMACEUTICAL, CORP. STOCK BONUS PLAN (As amended on March 1, 2004) l. Purpose. The purpose of this Stock Bonus Plan is to advance the interests of L.A.M. Pharmaceutical, Corp. (the ?Company?) and its shareholders, by encouraging and enabling selected officers, directors, consultants and key employees upon whose judgment, initiative and effort the Company is largely dependent |
|
| October 20, 2004 |
As filed with the Securities and Exchange Commission on October 20, 2004. S-8 1 g91350sv8.htm L.A.M. PHARMACEUTICAL, CORP. Table of Contents As filed with the Securities and Exchange Commission on October 20, 2004. Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 L.A.M. PHARMACEUTICAL, CORP. (Exact name of registrant as specified in its charter) Delaware 52-2278236 ( |
|
| October 20, 2004 |
Non-Qualified Stock Option Plan Exhibit 10.6 L.A.M. PHARMACEUTICAL CORP. NON-QUALIFIED STOCK OPTION PLAN (As amended on March 1, 2004) l. Purpose. This Non-Qualified Stock Option Plan (the ?Plan?) is intended to advance the interests of L.A.M. Pharmaceutical Corp. (the ?Company?) and its shareholders, by encouraging and enabling selected officers, directors, consultants and key employees upon whose judgment, initiative and effor |
|
| October 13, 2004 |
LAM Pharmaceutical Corp Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB/A Amendment No. |
|
| October 13, 2004 |
Distributorship Agreement w/ Verus S.A. de C.V. EX-10.6 2 g90890a3exv10w6.htm DISTRIBUTORSHIP AGREEMENT W/ VERUS S.A. DE C.V. Exhibit 10.6 DISTRIBUTORSHIP AGREEMENT This Agreement is made as of the 12th day of November, 2003, between: LAM PHARMACEUTICAL CORPORATION, a corporation subsisting under the laws of Delaware, and having a business address at 800 Sheppard Avenue West, Commercial Unit 1, Toronto, Ontario, Canada M3H 6B4. (hereinafter “LA |
|
| October 13, 2004 |
Distributorship Agreement w/ China National EX-10.7 3 g90890a3exv10w7.htm DISTRIBUTORSHIP AGREEMENT W/ CHINA NATIONAL Exhibit 10.7 DISTRIBUTORSHIP AGREEMENT This Agreement is made as of the 30th day of January, 2004, between LAM PHARMACEUTICAL CORPORATION, a corporation subsisting under the laws of Delaware, United States of America and having a business address at 800 Sheppard Avenue West, Commercial Unit 1, Toronto, Ontario, Canada M3H 6B |
|
| October 13, 2004 |
L.A.M. Pharmaceutical, Corp. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB/A Amendment No. 1 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2003 Commission File No. 000-30641 L.A.M. PHARMACEUTICAL, CORP. (Exact name of registrant as specified in charter) Delaware 52- |
|
| October 13, 2004 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB/A Amendment No. |
|
| October 13, 2004 |
As filed with the Securities and Exchange Commission on October 13, 2004 Table of Contents As filed with the Securities and Exchange Commission on October 13, 2004 Registration No. |
|
| September 9, 2004 |
As filed with the Securities and Exchange Commission on September 8, 2004 Table of Contents As filed with the Securities and Exchange Commission on September 8, 2004 Registration No. |
|
| August 13, 2004 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB ? Quarterly Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2004 or o Transition Report under Section 13 or 15 (d) of the Securities Exchange Act of 1934 Commission file No. |
|
| July 28, 2004 |
As filed with the Securities and Exchange Commission on July 27, 2004 Table of Contents As filed with the Securities and Exchange Commission on July 27, 2004 Registration No. |
|
| May 14, 2004 |
LAM Pharmaceuticals Inc. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB [X] Quarterly Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2004 or [ ] Transition Report under Section 13 or 15 (d) of the Securities Exchange Act of 1934 Commission file No. 000-30641 L.A.M. PHARMACEUTICAL, |
|
| May 4, 2004 |
As filed with the Securities and Exchange Commission on May 4, 2004 Table of Contents As filed with the Securities and Exchange Commission on May 4, 2004 Registration No. |
|
| January 26, 2004 |
SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| January 20, 2004 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934* (Amendment No. 3) L.A.M. PHARMACEUTICAL CORP. (Name of Issuer) Common Stock (Title of Class of Securities) 50172A 10 4 (CUSIP Number) Capital Research Group, Inc. 1825 Main Street Suite 201 Weston, Fl 33326 954 217- 8555 (Name, Address and Telephone Number of Person Autho |
|
| January 14, 2004 |
Captial Research Group UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 12, 2004 |
SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| December 5, 2003 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934* (Amendment No. 1) L.A.M. PHARMACEUTICAL CORP. (Name of Issuer) Common Stock (Title of Class of Securities) 50172A 10 4 (CUSIP Number) Capital Research Group, Inc. 1825 Main Street Suite 201 Weston, Fl 33326 954 217- 8555 (Name, Address and Telephone Number of Person Autho |
|
| December 3, 2003 |
SC 13D 1 g86155sc13d.htm CAPITAL RESEARCH GROUP, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934* (Amendment No. ) L.A.M. PHARMACEUTICAL CORP. (Name of Issuer) Common Stock (Title of Class of Securities) 50172A 10 4 (CUSIP Number) Capital Research Group, Inc. 1825 Main Street Suite 201 Weston, Fl 33326 954 217- 855 |
